134 related articles for article (PubMed ID: 35504200)
1. Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma.
Zhou B; Zang R; Zhang M; Song P; Liu L; Bie F; Peng Y; Bai G; Gao S
Int Immunopharmacol; 2022 Aug; 109():108816. PubMed ID: 35504200
[TBL] [Abstract][Full Text] [Related]
2. Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
Zhou F; Wang M; Wang Z; Li W; Lu X
BMC Cancer; 2024 Jan; 24(1):28. PubMed ID: 38166691
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
4. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
[TBL] [Abstract][Full Text] [Related]
5. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
Front Immunol; 2021; 12():755401. PubMed ID: 34917077
[TBL] [Abstract][Full Text] [Related]
6. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
7. An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma.
Han T; Liu Y; Wu J; Bai Y; Zhou J; Hu C; Zhang W; Guo J; Wang Q; Hu D
Sci Rep; 2023 Mar; 13(1):5153. PubMed ID: 36991102
[TBL] [Abstract][Full Text] [Related]
8. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
9. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
10. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
11. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential tumor antigens and immune subtypes for lung adenocarcinoma.
Bai M; Liu X; Wang L
Med Oncol; 2023 Feb; 40(3):100. PubMed ID: 36809467
[TBL] [Abstract][Full Text] [Related]
13.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
15. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
17. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
[TBL] [Abstract][Full Text] [Related]
18. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
19. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
20. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
